Role of leukocytes in the activation of intravascular coagulation in patients with septicemia.
To elucidate the role of leukocytes in intravascular coagulation in patients with septicemia, plasma levels of thrombin-antithrombin III complex (TAT), soluble fibrin monomer complex (SFMC) and fibrinogen (Fbg) were determined in 33 patients with septicemia. Twenty of 33 patients revealed marked leukopenia caused by suppression of hematopoiesis by the administration of chemotherapeutic agents for the treatment of hematological malignancies; the total leukocyte count of these patients was less than 1,000/microliters. Thirteen of 33 patients showed normal or increased leukocyte counts. Plasma levels of TAT and SFMC in septicemic patients without leukopenia were significantly higher than in patients with leukopenia. Although plasma TAT and SFMC levels correlated well with the number of leukocytes, a more significant positive correlation was found between the number of monocytes and the levels of TAT and SFMC. Plasma levels of Fbg were significantly lower in patients without leukopenia than in patients with leukopenia. No significant correlation was found between the number of leukocytes and the levels of Fbg. However, a significant negative correlation was found between the number of monocytes and the levels of Fbg. TAT levels did not correlate with the number of platelets. The fibrinolytic system was activated only in septicemic patients without leukopenia, which may be explained by secondary fibrinolysis following leukocyte-activated coagulation. These findings suggest that leukocytes, in particular monocytes, may play a critical role in the pathogenesis of intravascular coagulation in septicemia.
Okajima
K
K
Department of Laboratory Medicine, Kumamoto University Medical School, Japan.
Yang
W P
WP
Okabe
H
H
Inoue
M
M
Takatsuki
K
K
D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology; D004903:Erythrocyte Aggregation / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D007962:Leukocytes / Q000502:physiology*; D007970:Leukopenia / Q000097:blood / Q000150:complications; D010447:Peptide Hydrolases / Q000378:metabolism; D018805:Sepsis / Q000097:blood* / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D000979:alpha-2-Antiplasmin / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; C046193:antithrombin III-protease complex; C011468:fibrinmonomer; C024668:plasmin-alpha(2)-macroglobulin complex; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin